Philosophy
The Collegium Medicum was founded in th 17th Century in Prussian Berlin.
It quickly envolved into a network of excellence in which numerous medical professions worked together for the benefit of the patient.
In keeping with this tradition the idea of Collegium Medicum Berlin is to bring professionals from various fields of the health and medical industries together to create innovation and added value for patients by means of clinical trials.
Mission Statement
„We strive for a corporate culture in which employees are committed to the company for the longterm, involved in major decision-making processes in a trusting and respectful environment.“
„We focus on longterm cooperation with our partners and clients, thereby aiming to maximise satisfaction for all partners.“
„We implement study projects for our clients with maximum efficacy and efficiency.“
SERVICES
We offer our services related to clinical trials for sponsors and physicians of all disciplines.
- Provision of expertise and resources
- Assistance in the regulatory process and audits
- Medical and business advice
MANAGEMENT TEAM
Our main expertise include extensive knowledge in the areas of clinical trials coupled with international cooperation as well as many years of experience in academic medicine. The business and strategic advisory expertise of the CMB is based on years of participation in international consulting firms as well as an extensive network of economic and political contacts in Berlin, Germany as well as interational.
Dr. Martina UlrichMedical Management, Dermatologist, Manager and Shareholder
Curriculum Vitae
Qualifications
| 2014 | Training and qualification of "Dermatohistology" |
| Since 2005 | Non-invasive diagnosis of skin diseases, in-vivo reflectance confocal microscopy, optical coherence tomography, multiphoton tomography |
| Since 2005 | Conception and performance of clinical trials focusing on skin cancer treatment and diagnostics (Skin Cancer Center, Lead: Prof. Stockfleth, Charité – Universitätsmedizin Berlin) |
| 2010 - 2013 | Training for the qualification of „Dermatopathology“ (Prof. Sterry/Prof. Haas/Prof. Röwert-Huber, at the Department of Dermatology, Charité – Universitätsmedizin Berlin) |
| 2010 - 2013 | Training for the qualification of “Medikamentöse Tumortherapie” at the Department of Dermatology (Skin Cancer Center, Lead: Prof. Stockfleth, Charité – Universitätsmedizin Berlin) |
| 2011 | AWMF Guideline “Konfokale Lasermikroskopie” (confocal laser scanning microscopy) in cooperation with Dr. Lange-Asschenfeldt, Prof. Welzel und Prof. Hohenleutner |
Workexperience
| Since 2014 | CEO of CMB Collegium Medicum Berlin GmbH |
| Since 2013 | Private dermatology office and medical director of CMB Collegium Medicum Berlin GmbH |
| 2010 - 2013 | Consultant dermatologist at the Department of Dermatology, Charité – Universitätsmedizin Berlin |
| 2005 - 2010 | Residency at the Department of Dermatology, Charité - Universitätsmedizin Berlin |
| 2004 - 2005 | Grant „International training program for dermatology“ Harvard Medical School, Boston, USA |
Study assistance and coordination
Curriculum Vitae
Qualifications
| 2011 | Studienassistent im Prüfzentrum, KKS Charité Berlin |
| 2009 | English for Study personnal, KKS Charité Berlin |
| 2008 | Grundlagenkurs Klinische Studien, KKS Charité Berlin |
| 1998 - 2002 | Biochemistry study, Johann-Wolfgang-Goethe Universität Frankfurt |
| 1991 | Examination as physician assistant, Frankfurt am Main |
| Biochemistry study, Johann-Wolfgang-Goethe |
Work experience
| since 2013 | Study Nurse, Collegium Medicum Berlin |
| Trials phase I-IV, indications: | |
| Therapy of actinic keratosis | |
| Diagnosis of basal cell carcinoma | |
| Therapy of basal cell carcinoma | |
| 2011 - 2013 | Centre for Muscel and Bone Research, Charité Berlin |
| Trials phase III, indications: | |
| Prophylaxis of fracture by osteoporosis, Fracturehealing by osteoporosis, Theraphy of osteoporosis | |
| 2010 - 2011 | ClinicalResearchCenter, Charité Berlin |
| Trials phase II-IV, indications: | |
| Prophylaxis of male hairloss, Therapy of male and femal hairloss, Rosacea | |
| 2007 - 2009 | Franziskus-Krankenhaus, Berlin |
| Trials phase II-IV, indications: | |
| Prophylaxis of thrombosis, Therapy of thrombosis, | |
| Diabetes mellitus, Therapy of p.a.o.d., Critical limb ischaemia, Prophylaxis of stroke by atrial fibrillation |
References
A multi-centre, randomized, double-blind, parallel-group, placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules Compared to Placebo for the Treatment of Inflammatory Lesions of Rosacea over 16 Weeks –
EudraCT-Nr. 2016-003197-41
Imi-C - Double-blind, randomised clinical study comparing efficacy and safety of Imiquimod 5% Cream (Test) vs. Aldara (R) 5% Cream (Reference) vs. Vehicle in patients with actinic keratosis – EudraCT-Nr. 2016-000712-15
ECZTRA1 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up LP0084-1014 (Phase I, multizentrisch, einarmig, open-label, 8 Wochen Dauer) LEO-Pharma GmbH, EudraCT-Nr. 2012-004191-20 –
(Phase III, multicentre, randomized. parallel group, double-blind, vehicle-controlled trial) LEO-Pharma GmbH, EudraCT-Nr. 2015-002450-12
LP0084-1369 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up LP0084-1014 (Phase I, multizentrisch, einarmig, open-label, 8 Wochen Dauer) LEO-Pharma GmbH, EudraCT-Nr. 2012-004191-20 –
(Phase III, multicentre, randomized. parallel group, double-blind, vehicle-controlled trial) LEO-Pharma GmbH, EudraCT-Nr. 2015-002450-12
Comparison of 2 different plasters after removal of a superficial Seborrhoic Keratosis, Urgo - NIS
LP0084-1194 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest including 12-month follow-up LP0084-1014 (Phase I, multizentrisch, einarmig, open-label, 8 Wochen Dauer) LEO-Pharma GmbH, EudraCT-Nr. 2012-004191-20 –
(Phase III, multicentre, randomized. parallel group, double-blind, vehicle-controlled trial) LEO-Pharma GmbH, EudraCT-Nr. 2015-002450-12
A Phase III, Randomized, Placebo-controlled, Paralell-Group, Double-Blind Clinical Trial to Study The Efficacy and Safety of MK-8931 (SCH900931) in Subjects with Anmnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD), MSD/Merck – EudraCT-NR. 2011-003151-20
ADVANCE - Automatic Detection of Vascular Networks for Cancer Evaluation - Michelson Diagnostics Ltd. - NIS
Randomised, placebocontrolled, multicentre doubleblind study with parallel group design for safety and efficacy of Acktikerall lotion by treatmentareas on the head with Actinic Keratoses grad I - II, Almirall – EudraCT-Nr. 2014-001171-31
ALA-BCC-CT008 - Efficacy and safety in the treatment of basalcellcarcinomas in comparison with two approved drugs for photodynamic therapie (Phase III, multicentre, singlearm, open-label, 8 weeks duration) LEO-Pharma GmbH, EudraCT-Nr. 2012-004191-20 –
Randomised, placebocontrolled doubleblind study with parallel group design for safety and efficacy of MK-8931 with patients with mild to moderate Alzheimer‘s disease, MSD bzw. Merck - EudraCT-Nr. 2011-003151-20
Histological confirmation of clinical healing of actinic keratosis after treatment with Ingolmebutat-Gel, 0.05% LP0041-062 (Phase I, multicenter, single-arm, open-label, 8 weeks in duration) LEO-Pharma GmbH, EudraCT-Nr. 2012-004191-20
BCC-OCT-NIS - Evaluation of optical coherence tomography fort he diagnosis of basal cell carcinoma, Michelson Diagnostics Deutschland GmbH
Michelson Diagnostics Deutschland GmbH for several appointments skin cancer diagnosis using optical coherence tomography in daily dermatological practice
Almirall Nordic, DK-Hellerup for the implementation and organisation of the 1st Scandinavian Skin Cancer Summit vom 26. – 27.04.13